GSK Vaccines NA RDC: Project rationale review and Key Performance Indicators selection

GSK Vx is currently reviewing its distribution Network Strategy. The current distribution network is highly concentrated in Europe with direct shipments by air to the clients. The distribution center in Gembloux is responsible for 80% of the vaccines volume shipped to clients worldwide. This fragmented view and control of the distribution lead to a supply continuity and security risk. The new model will consist on the implementation of regional distribution centers to push the products closer to the markets. To implement the new model, a pilot project has been designed, the NA RDC. The project is to implement a distribution center in the US that will be responsible of supplying US, Canada and Mexico markets. For such a project to be endorsed, a presentation has been done to the higher management. The thesis will consist in the review of the business case that supported the management endorsement and the building of KPI associated to prove the project impact and benefits. The goal was to create a framework using literature from different fields. Vaccine distribution network and performance literature combined with decentralized vs decentralized literature has been used to create a list of attention points regarding vaccine decentralized distribution. The SCOR and SMART models have been used to ensure the quality and strategic relevance of the KPI that were built. The outcome was a list of KPI based on the review of the business case that the author conducted.